Harte Hanks acquires exclusive rights to license ADS' Medical Ailment Database
Exclusive Licensing Agreement: Harte Hanks has secured exclusive rights to license ADS Data Direct's Medical Ailment Database, enhancing its position in the healthcare marketing sector with a comprehensive, HIPAA-compliant data asset.
Enhanced Targeting Capabilities: The database offers access to triple opt-in consumers identified with specific health conditions across over 200 categories, improving targeting precision and campaign performance for clients in pharmaceuticals and medical devices.
Trade with 70% Backtested Accuracy
Analyst Views on HHS
About HHS
About the author
Friday 12/6 Insider Buying Report: DMLP, HHS
Dorchester Minerals Insider Purchase: CFO Leslie A. Moriyama purchased 12,050 shares of DMLP for $414,640 at $34.41 each, while the stock is currently trading lower at $33.00, indicating a potential buying opportunity for investors.
Harte Hanks Insider Purchase: Director Bradley Louis Radoff bought 42,775 shares of Harte Hanks for $241,551 at $5.65 each, with the stock up about 3.6% on Friday, reflecting an 8.0% gain based on current trading prices.
Harte-Hanks (HHS) Q3 Earnings and Revenues Top Estimates
Earnings Performance: Harte-Hanks reported quarterly earnings of $0.13 per share, exceeding estimates and showing a year-over-year increase from $0.08. The company also surpassed revenue expectations with $47.63 million for the quarter.
Market Outlook: Despite recent earnings success, Harte-Hanks shares have underperformed compared to the S&P 500 this year, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Integral Ad Science (IAS) Q3 Earnings Top Estimates
Earnings Performance: Integral Ad Science (IAS) reported quarterly earnings of $0.10 per share, exceeding estimates and showing improvement from a loss of $0.09 per share a year ago, although revenues fell short of expectations at $133.53 million.
Market Outlook: IAS shares have underperformed the market this year, with a Zacks Rank of #3 (Hold), indicating expected performance in line with the market; future stock movements will depend on management's commentary and earnings estimate revisions.
Harte-Hanks (HHS) Flat As Market Gains: What You Should Know
Harte-Hanks Stock Performance: Harte-Hanks (HHS) closed at $6.98, unchanged from the previous day, while experiencing a 5.55% loss over the past month, underperforming compared to the Business Services sector and S&P 500 gains. The company is set to release its earnings report on November 14, 2024, with expectations of a 25% year-over-year growth in earnings.
Analyst Estimates and Zacks Rank: The Zacks Consensus Estimates predict a significant decline in annual earnings and revenue for Harte-Hanks, currently holding a Zacks Rank of #3 (Hold). The Zacks Rank system indicates that stocks rated #1 (Strong Buy) have historically outperformed others, suggesting potential investment strategies based on analyst estimate changes.
Harte-Hanks (HHS) Stock Moves -0.68%: What You Should Know
Stock Performance: Harte-Hanks (HHS) closed at $7.25, down 0.68%, underperforming compared to the S&P 500 and other indices; the company has seen a 4.33% decline over the past month, while analysts expect an EPS of $0.10 in the upcoming earnings report.
Analyst Insights: The Zacks Rank system rates Harte-Hanks as #3 (Hold), reflecting stagnant EPS estimates, while the Advertising and Marketing industry ranks in the top 23% of all industries, indicating potential for future stock performance based on estimate revisions.
Harte-Hanks (HHS) Stock Falls Amid Market Uptick: What Investors Need to Know
Harte-Hanks Stock Performance: Harte-Hanks (HHS) closed at $7.30, down 0.41%, underperforming the S&P 500 and experiencing a 4.06% decline over the past month; upcoming earnings are projected to show a 25% increase in EPS year-over-year.
Analyst Forecasts and Zacks Rank: Analysts expect a challenging full year for Harte-Hanks with significant declines in earnings and revenue; the company currently holds a Zacks Rank of #3 (Hold), indicating average performance potential within the Advertising and Marketing industry.
Friday 12/6 Insider Buying Report: DMLP, HHS
Dorchester Minerals Insider Purchase: CFO Leslie A. Moriyama purchased 12,050 shares of DMLP for $414,640 at $34.41 each, while the stock is currently trading lower at $33.00, indicating a potential buying opportunity for investors.
Harte Hanks Insider Purchase: Director Bradley Louis Radoff bought 42,775 shares of Harte Hanks for $241,551 at $5.65 each, with the stock up about 3.6% on Friday, reflecting an 8.0% gain based on current trading prices.
Harte-Hanks (HHS) Q3 Earnings and Revenues Top Estimates
Earnings Performance: Harte-Hanks reported quarterly earnings of $0.13 per share, exceeding estimates and showing a year-over-year increase from $0.08. The company also surpassed revenue expectations with $47.63 million for the quarter.
Market Outlook: Despite recent earnings success, Harte-Hanks shares have underperformed compared to the S&P 500 this year, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Integral Ad Science (IAS) Q3 Earnings Top Estimates
Earnings Performance: Integral Ad Science (IAS) reported quarterly earnings of $0.10 per share, exceeding estimates and showing improvement from a loss of $0.09 per share a year ago, although revenues fell short of expectations at $133.53 million.
Market Outlook: IAS shares have underperformed the market this year, with a Zacks Rank of #3 (Hold), indicating expected performance in line with the market; future stock movements will depend on management's commentary and earnings estimate revisions.
Harte-Hanks (HHS) Flat As Market Gains: What You Should Know
Harte-Hanks Stock Performance: Harte-Hanks (HHS) closed at $6.98, unchanged from the previous day, while experiencing a 5.55% loss over the past month, underperforming compared to the Business Services sector and S&P 500 gains. The company is set to release its earnings report on November 14, 2024, with expectations of a 25% year-over-year growth in earnings.
Analyst Estimates and Zacks Rank: The Zacks Consensus Estimates predict a significant decline in annual earnings and revenue for Harte-Hanks, currently holding a Zacks Rank of #3 (Hold). The Zacks Rank system indicates that stocks rated #1 (Strong Buy) have historically outperformed others, suggesting potential investment strategies based on analyst estimate changes.
Harte-Hanks (HHS) Stock Moves -0.68%: What You Should Know
Stock Performance: Harte-Hanks (HHS) closed at $7.25, down 0.68%, underperforming compared to the S&P 500 and other indices; the company has seen a 4.33% decline over the past month, while analysts expect an EPS of $0.10 in the upcoming earnings report.
Analyst Insights: The Zacks Rank system rates Harte-Hanks as #3 (Hold), reflecting stagnant EPS estimates, while the Advertising and Marketing industry ranks in the top 23% of all industries, indicating potential for future stock performance based on estimate revisions.
Harte-Hanks (HHS) Stock Falls Amid Market Uptick: What Investors Need to Know
Harte-Hanks Stock Performance: Harte-Hanks (HHS) closed at $7.30, down 0.41%, underperforming the S&P 500 and experiencing a 4.06% decline over the past month; upcoming earnings are projected to show a 25% increase in EPS year-over-year.
Analyst Forecasts and Zacks Rank: Analysts expect a challenging full year for Harte-Hanks with significant declines in earnings and revenue; the company currently holds a Zacks Rank of #3 (Hold), indicating average performance potential within the Advertising and Marketing industry.
